Huons to challenge to next-generation anticoagulant ‘Pradaxa’ for first time
Huons will challenge to development of Pradaxa generics for the first time among other domestic pharmaceutical companies.
According to the Ministry of Food and Drug Safety(MFDS), Huons acquired approval for a bioequivalence test to develop Pradaxa generics on the last 9th. Huons is the only comp...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
